Real-world analysis and future trends of parkinson's disease burden and all-cause mortality in Shanghai Pudong: a population-based study of 3.17 million people

上海浦东帕金森病负担和全因死亡率的真实世界分析及未来趋势:一项基于317万人的人口研究

阅读:3

Abstract

BACKGROUND: To assess all-cause Parkinson's disease (PD)-related and PD-specific mortality trends and years of life lost (YLL) in Shanghai Pudong (3.17 million population) from 2005-2021, and project future burdens through 2035. METHODS: Using population-level mortality data including 4,218 PD-related deaths among 362,558 total deaths, we calculated crude mortality rates (CMR), age-standardized mortality rates (ASMRW), and YLL. Temporal trends were analyzed by the average annual percent change (AAPC) via Joinpoint regression, demographic impacts via decomposition methods, and future projections via ARIMA models. RESULTS: PD-related CMR and ASMRW were 8.74/100,000 and 2.76/100,000, respectively, with 31,904.41 YLL. PD-specific mortality rates (CMR: 3.76/100,000; ASMRW: 1.25/100,000) accounted for 14,532.50 YLL. Individuals aged ≥ 80 years exhibited highest mortality burden (CMR: 112.29/100,000). Cerebrovascular disease (18.94%) and coronary heart disease (13.54%) were leading comorbidities. Temporal analyses revealed significant annual increases in ASMRW (AAPC = 8.38%, P < 0.001) and YLL rates (AAPC = 7.03%, P < 0.001), driven predominantly by population aging (AAPC = 30.73%, P < 0.001). Projections indicate continued rises in ASMRW (AAPC = 1.49%) and YLL rates (AAPC = 3.49%) through 2035 (P < 0.001). CONCLUSIONS: PD imposes increasing mortality burden in Shanghai Pudong, with population aging as the primary driver. Multi-departmental interventions targeting early diagnosis, comorbidity management, and medical infrastructure are urgently needed. TRIAL REGISTRATION: Clinical trial number: not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。